Kilitch Drugs (India) Ltd
NSE:KILITCH
Net Margin
Kilitch Drugs (India) Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
IN |
K
|
Kilitch Drugs (India) Ltd
NSE:KILITCH
|
5.8B INR |
11%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
824.9B USD |
24%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
373B USD |
24%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
35%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
211.5B CHF |
14%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
189B CHF |
23%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
163.2B GBP |
13%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
210.6B USD |
27%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
FR |
![]() |
Sanofi SA
PAR:SAN
|
116.7B EUR |
14%
|
Kilitch Drugs (India) Ltd
Glance View
Kilitch Drugs (India) Ltd. engages in the manufacture and sale of pharmaceuticals, medicinal chemical, and botanical products. The company is headquartered in Mumbai, Maharashtra. The company is primarily engaged in the development, manufacturing, and marketing of finished dosages. The Company’s products include parenteral solutions, effervescent, nutritional products, and medical device. Its products categories include urinary alkalizer, cephalosporins products, gastroenterology, non steroidal anti-inflammatory drugs (NSAIDs), anticonvulsant/antiepileptic, adrenergic agonist, neurotonic, muscle relaxant/stimulant, aminoglycosides, anti-infective, anti-inflammatory, anti-malarials, anti-hypertensive, anaesthetic, uterine stimulants. Its parenteral solutions include neurotonic, veterinary products, metered nasal drops, vaccines, oncology, and ophthalmic products. Its effervescent products include Roipar, Duregra, And Roivit. The firm offers nutritional products, such as Celtine. The firm also offers medical devices, such as C-Seal.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Kilitch Drugs (India) Ltd's most recent financial statements, the company has Net Margin of 10.7%.